(Total Views: 125)
Posted On: 10/02/2019 3:59:16 PM
Post# of 282
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices Public Offering; Subsidiary Sells 10 STREAMWAY Systems to Leading Teaching Hospital in New York
Predictive Oncology (NASDAQ: POAI) today announced pricing for the public offering of its common stock that the company announced in a news release on Tuesday. The company is offering 6,335,537 shares on a “best efforts” basis at a price of $0.50 each for anticipated gross proceeds of up to $3,167,768.50, before subtracting placement agent fees, expenses and offering expenses payable by POAI. Dawson James Securities, Inc. and Paulson Investment Company, LLC are acting as exclusive placement agents for the offering. Subject to customary closing conditions, the offering is projected to close on or about October 4, 2019.
In addition, Predictive Oncology announced this morning that its Skyline Medical division has finalized the sale of ten patented, FDA-approved STREAMWAY® systems to the leading teaching and research hospital in upstate New York. Skyline Medical’s STREAMWAY System is a continuous, direct-to-drain fluid disposal system designed precisely for medical applications such as radiology, endoscopy, surgery, urology, and cystoscopy procedures. This sale exceeds the company’s largest single hospital sale to date and is anticipated to generate 6000 procedures annually.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) today announced pricing for the public offering of its common stock that the company announced in a news release on Tuesday. The company is offering 6,335,537 shares on a “best efforts” basis at a price of $0.50 each for anticipated gross proceeds of up to $3,167,768.50, before subtracting placement agent fees, expenses and offering expenses payable by POAI. Dawson James Securities, Inc. and Paulson Investment Company, LLC are acting as exclusive placement agents for the offering. Subject to customary closing conditions, the offering is projected to close on or about October 4, 2019.
In addition, Predictive Oncology announced this morning that its Skyline Medical division has finalized the sale of ten patented, FDA-approved STREAMWAY® systems to the leading teaching and research hospital in upstate New York. Skyline Medical’s STREAMWAY System is a continuous, direct-to-drain fluid disposal system designed precisely for medical applications such as radiology, endoscopy, surgery, urology, and cystoscopy procedures. This sale exceeds the company’s largest single hospital sale to date and is anticipated to generate 6000 procedures annually.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
